Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Sima Jeha(St. Jude Children's Research Hospital), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center), Lisa Bomgaars(Stollery Children's Hospital), Timothy J. Griffin(University of Minnesota), Edythe A. Albano(Office of the Director), Susan R. Rheingold(Children's Hospital of Philadelphia), Paul S. Gaynon(University of Southern California), Richard Kadota(Roswell Park Comprehensive Cancer Center), Janet Franklin(Children's Hospital of Los Angeles), Stewart Goldman(St Nicholas Hospital), Bassem I. Razzouk(Peyton Manning Children’s Hospital at St.Vincent), Kim Ritchey(Children's Hospital of Orange County), Arnold J. Altman(Lyon 1 Université), Bruce G. Gordon(Children's Hospital of Orange County), Michael Rytting(The University of Texas MD Anderson Cancer Center), Laurel J. Steinherz(Children's Hospital of Orange County), R.J. Arceci(Johns Hopkins University), Steven Weitman(Children's Hospital of Orange County), Violet Shen(Ruhr University Bochum), Lori Luchtman‐Jones(Cincinnati Children's Hospital Medical Center)
Cited by 309
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
|Journal of Clinical Oncology|2011|839
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794